Healthcare services company Sotera Health (NASDAQ:) will be reporting results this Tuesday before market open. Here’s what you need to know.

Sotera Health Company beat analysts’ revenue expectations by 6.8% last quarter, reporting revenues of $294.3 million, up 6.4% year on year. It was a stunning quarter for the company, with an impressive beat of analysts’ organic revenue estimates and a solid beat of analysts’ revenue estimates.

Is Sotera Health Company a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, analysts are expecting Sotera Health Company’s revenue to grow 6.3% year on year to $303.5 million, slowing from the 8.5% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.22 per share.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Sotera Health Company has a history of exceeding Wall Street’s expectations, beating revenue estimates every single time over the past two years by 3% on average.

Looking at Sotera Health Company’s peers in the research tools & consumables segment, some have already reported their Q3 results, giving us a hint as to what we can expect. Thermo Fisher delivered year-on-year revenue growth of 4.9%, beating analysts’ expectations by 1.9%, and Revvity reported revenues up 2.2%, in line with consensus estimates. Thermo Fisher traded up 2.6% following the results while Revvity was down 2.4%.

Read our full analysis of Thermo Fisher’s results here and Revvity’s results here.

Investors in the research tools & consumables segment have had steady hands going into earnings, with share prices flat over the last month. Sotera Health Company is up 2.3% during the same time and is heading into earnings with an average analyst price target of $17 (compared to the current share price of $16.60).

When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.